Skip to main content
  • Covid-19

    Spike Protein Behavior

    I’ve been getting a lot of questions in the last few days about several Spike-protein-related (and vaccine-related) topics, so I thought this would be a good time to go into them. There’s been a recent report about the vascular effects of the Spike protein alone (not coronavirus infection per se), and another presentation on similar… Read More
  • Cancer

    Two Steps to Activation

    Engineering immune system cells to do what we’d like them to do is one of the big areas of medical research these days, and this new paper could be a real advance in the area. A team out of UCSF with several collaborators reports on a new way around one of the big problems in… Read More
  • Covid-19

    Russian Vaccine Behavior

    In the last post, I mentioned the Twitter response to the Brazilian rejection of the Gamaleya vaccine. I believe that the official blue-check-marked “Sputnik V” Twitter account is run by the Russian Direct Investment Fund, the sovereign-wealth part of the Russian state that is in charge of rolling out the vaccine to different countries. Read More
  • Covid-19

    Brazil Rejects the Gamaleya Vaccine

    We have two pieces of news about the Gamaleya Institute’s “Sputnik-V” vaccine today. Neither of them are going to be enjoyable to go into. First off, many may have heard that the Brazilian regulatory authorities had a hearing yesterday to see if this vaccine would be approved for use there. They have turned it down… Read More
  • Analytical Chemistry

    Watery Worlds

    One of the themes of chemistry over the last few decades has been the ability to pay attention to increasingly fine-grained details. We have new instruments that measure smaller and smaller samples and in shorter slices of time, and we’re seeing that the world that we’ve been used to is just an averaged-out look at… Read More
  • Infectious Diseases

    Great Malaria Vaccine News

    Excellent news today: we have word of the most effective malaria vaccine yet discovered. A year-long trial in Burkina Faso has shown 77% efficacy, which is by far the record, and which opens the way to potentially relieving a nearly incalculable burden of disease and human suffering. This is a collaboration between the University of… Read More
  • Covid-19

    A Look at Novavax

    Lots of work going on today, so let me just send the readership to this excellent article about Novavax, by Jason Mast at Endpoints. That vaccine has moved into even more prominence lately with the recent adenovirus vaccine events, and it seems clear that it could be a big part of getting the world vaccinated. Read More
  • Clinical Trials

    Moderna’s Upcoming Clinical Trials

    One of the ways in which this pandemic will be looked back on as a pivot point will (almost certainly) be in the use of mRNA vaccines. It seems clear at this point that these have come through spectacularly against the coronavirus: every new study of their effects in the broad population just adds to… Read More
  • Business and Markets

    The Money Keeps On Comin’

    I enjoyed this post by Bruce Booth on the biopharma funding landscape. But I think we would all agree that. . .well, it’s been weird the last few years. This has been a long, long boom in the amount of money that’s flowed into this sector, and I don’t think I’ve ever seen anything like… Read More
  • Chemical News

    New Electron Tricks in Synthetic Chemistry

    One of specialties of Phil Baran’s group at Scripps the last few years has been electrosynthesis, which has a traditional hmm-interesting-turn-the-page reputation among most synthetic chemists that they’re trying to change. Photochemistry was in roughly the same category at one time, and has become much more mainstream (although it alwa… Read More